Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Neurol Neurosurg ; 113(4): 277-80, 2011 May.
Article in English | MEDLINE | ID: mdl-21159421

ABSTRACT

OBJECTIVES: To report the results from the Brazilian database on multiple sclerosis (MS) and pregnancy. METHODS: Retrospective data from MS patients who became pregnant at any time of their disease were sent to a Brazilian database, using a specific file for this purpose. RESULTS: Data on 128 women (142 pregnancies) from 30 neurologists working in 21 cities in Brazil were collected. Patients' average age at pregnancy was 29.8 years (range 16-42). EDSS at start of pregnancy was 1.5±1.4; and the relapse rate in the year preceding pregnancy was 1.2±1.5. Exposure to medication at any time during pregnancy was high (69.7%): 48.6% to interferon beta; 14.1% to glatiramer acetate; and 7% to other immunomodulatory and immunosuppressive drugs. There was a significant decrease in relapse rate during pregnancy. The prevalence of complications was relatively low, with 4.9% of obstetric and 1.4% neonatal unfavorable outcomes. CONCLUSIONS: Our patients had low degrees of disability, short histories of disease, high drug exposure, and relatively high relapse rate in the year previous to pregnancy. Obstetric and neonatal outcomes were successful in over 90% of our patients.


Subject(s)
Multiple Sclerosis/epidemiology , Pregnancy Complications/epidemiology , Adolescent , Adult , Birth Weight/drug effects , Brazil/epidemiology , Data Interpretation, Statistical , Databases, Factual , Female , Glatiramer Acetate , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Infant, Newborn , Infant, Newborn, Diseases/epidemiology , Interferon Type I/adverse effects , Interferon Type I/therapeutic use , Multiple Sclerosis/drug therapy , Peptides/adverse effects , Peptides/therapeutic use , Pregnancy , Pregnancy Outcome , Recombinant Proteins , Recurrence , Retrospective Studies , Young Adult
2.
Mult Scler ; 16(1): 81-6, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19995833

ABSTRACT

Neuromyelitis optica has not been thoroughly studied in Brazilian patients following the discovery of NMO-IgG and its specific antigen aquaporin-4. In this study we aimed to describe the clinical NMO-IgG immunological status and neuroimaging characteristics of recurrent neuromyelitis optica in a series Brazilian patients. We undertook a retrospective study of 28 patients with recurrent neuromyelitis optica, according to 1999 Wingerchuk's diagnostic criteria. Data on NMO-IgG status, clinical features, and MRI findings were analyzed. Three men and 25 women were evaluated. Median age at onset of disease was 26 years (range 7-55); median time of follow-up was 7 years (range 2-14). The mean time elapsed between the first and the second attack was 17 months (median 8.5; range 2-88). NMO-IgG was detected in 18 patients (64.3%). Four patients died due to respiratory failure. Most patients presented with cervical (36%) and cervical-thoracic myelitis (46.4%). Holocord lesion was the most common pattern of involvement (50%) on the axial plane. We did not find a statistical association between myelitis extension and NMO-IgG result. Our series of Brazilian patients showed a younger age of onset than previously reported. In our series, in contrast to previous reports, there was no correlation between the extension of myelitis and NMO-IgG positivity.


Subject(s)
Neuromyelitis Optica/pathology , Adolescent , Adult , Age of Onset , Brain/pathology , Brazil/epidemiology , Child , Female , Humans , Immunoglobulin G/analysis , Longitudinal Studies , Magnetic Resonance Imaging , Male , Middle Aged , Neuromyelitis Optica/epidemiology , Neuromyelitis Optica/immunology , Recurrence , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...